2026 NCODA INTERNATIONAL FALL SUMMIT | Essential CE Information

1 REGISTER FOR CEs

Click link below or scan QR code

https://www.lecturepanda.com/r/2026NCODAFallSummit

After registering, you will receive a confirmation email from lecturepanda with a unique link. **Please do not share this link, it is unique to your profile.**

2 COMPLETE THE PRE-ASSESSMENT

Please complete the pre-assessment quiz for each CE activity before the session begins.

Pre-assessments close 15 minutes after each CE session begins.

3 OBTAINING CE CREDIT

Complete all LecturePanda credit requirements within 60 days, by:

DEC
29

Pharmacists; Pharmacy Technicians:

- ACPE credit transmitted electronically

Physicians; Nurses; Nurse Practitioners; Physician Assistants:

- Refer to the PACE handout

2026 NCODA INTERNATIONAL FALL SUMMIT

2026 NCODA Fall Summit CE Poster Presentations

Claim 1 Hour of Live Continuing Education Credit

Date & Time

Thursday, October 29 | 5:15 – 6:15 PM

Location

Palms Ballroom

CE CODE | 2026 NCODA INTERNATIONAL FALL SUMMIT

Q8QN7P

How to Claim Your CE Credit

1. **Attend and participate in the live CE poster session.**
2. **Return to LecturePanda and enter the CE claim code above**
3. **Complete the required CE Post-Assessment and Evaluation**

Complete all Live CE requirements in LecturePanda by **December 29, 2026**

Partners for Advancing Clinical Education

2026 NCODA Fall Summit
Physician, Nurse, Nurse Practitioner, Physician Assistant Sessions
CE Information

October 28 - 30, 2026 | Orlando, FL
Provided by Partners for Advancing Clinical Education and NCODA

Target Audience

This conference is intended for oncology healthcare providers that include; pharmacists, pharmacy technicians, physicians, physician assistants, nurses, and nurse practitioners who care for patients within oncology

Session Educational Objectives

Upon completion of this session, participants should be able to:

Future of ADCs: Preparing Practices for What's Coming
0.75 AMA PRA Category 1 Credit™, AAPA credit and ANCC contact hour
This educational activity is supported by an independent medical education grant from GSK.

- Describe current approved indications and the expansion of antibody–drug conjugates (ADCs) into earlier lines of therapy and evolving combination regimens.
- Explain how novel payloads, emerging biomarkers, bispecific ADCs, and combinations of ADCs with bispecific antibodies may influence patient selection and treatment sequencing.
- Identify operational implications of evolving ADC therapies for oncology practices, including biomarker testing, agent-specific toxicity monitoring, patient counseling, and interprofessional care coordination.

Navigating the Evolving Multiple Myeloma Treatment Landscape: Bispecifics, CAR-T, & CELMoDs
1.0 AMA PRA Category 1 Credit™, AAPA credit and ANCC contact hour

- Review the evolving role of CAR T-cell therapy, bispecific antibodies, and CELMoDs in the management of relapsed/refractory multiple myeloma, including considerations for treatment selection and sequencing.
- Describe evidence-based strategies for recognizing, grading, and managing treatment-related toxicities associated with CAR T-cell therapy and bispecific antibodies, including cytokine release syndrome (CRS), neurotoxicity (ICANS), and infection risk.
- Discuss operational and workflow considerations for implementing bispecific antibody therapy in community oncology practice, including step-up dosing, patient monitoring, interdisciplinary communication, and coordination of care.
- Identify the roles of oncology multidisciplinary team in supporting safe medication-use processes, treatment coordination, and patient education for emerging multiple myeloma therapies.
- Outline practical approaches to optimizing patient outcomes through multidisciplinary management of patients receiving CAR T-cell therapy, bispecific antibodies, and novel CELMoD therapies.

1:45-2:45 pm Breakout Sessions (concurrent)
1.0 AMA PRA Category 1 Credit™, AAPA credit and ANCC contact hour

Advancing Care in Low-Grade Serous Ovarian Cancer: Integrating Molecular Testing Into Clinical Decision Making
This educational activity is supported by an independent medical education grant from Verastem, Inc.

- Describe the molecular and biological characteristics of low-grade serous ovarian cancer (LGSOC), including key differences from other ovarian cancer subtypes.
- Identify recommended molecular testing approaches in ovarian cancer, including biomarkers relevant to LGSOC.
- Discuss current and emerging treatment strategies for patients with LGSOC based on molecular and clinical factors.
- Interpret molecular testing results from patient-case examples to guide treatment selection and clinical decision-making in LGSOC.

From Prescription to Persistence: Optimizing Access & Adherence Across the OAM Journey

- Describe how the NCODA/ONS Oral Anticancer Medication (OAM) Care Compass may be used to address barriers to cancer care
- Examine the role of workflow ownership in a formal OAM program to reduce gaps in care.
- Compare approaches used by formal versus informal OAM programs to address barriers across the patient journey.
- Demonstrate application of available resources to address workflow gaps within individual practice settings through group activity.

2:45-3:45 pm Breakout Sessions (concurrent)

1.0 AMA PRA Category 1 Credit™, AAPA credit and ANCC contact hour

Fixed Duration, Forward Thinking: Evolving CLL Treatment

- Discuss the key clinical evidence, safety profiles, and practical considerations associated with fixed-duration treatment approaches in chronic lymphocytic leukemia
- Apply patient- and disease-specific factors that influence the selection of fixed-duration therapy in CLL through case-based examples.
- Identify patient-specific factors that warrant pharmacist review when supporting fixed-duration therapy in CLL through case-based examples.

Protecting Future Possibilities: Integrating Fertility Preservation Across the Cancer Care Continuum

- Discuss treatment-related infertility risks, fertility preservation options, and reproductive health considerations for pediatric, adolescent and young adult, and adult patients within multidisciplinary oncology care.
- Apply patient-centered communication and shared decision-making strategies regarding fertility preservation in patient case scenarios across the cancer care continuum.

Thinking Beyond the Task: Strengthening Clinical Judgment & Accountability in Oncology Nursing

- Describe how Tanner's Clinical Judgment Model (noticing, interpreting, responding, reflecting) applies to evolving clinical concerns, including infusion-related reactions (IRR) and triage/telephone symptom management in a variety of oncology settings.
- Discuss how culture of safety, near-miss/miss reporting, and systems-level factors support or constrain clinical judgment at the point of care.
- Explain how clinicians across Benner's novice-to-expert continuum contribute differently, with advanced beginners bringing transferable safety knowledge from prior settings to inform systems and protocols, and experts bringing pattern recognition to the bedside.
- Outline how principles of accountability and emotional intelligence inform an appropriate clinical response in a case-based infusion scenario.

The New Access Landscape: Preparing Oncology Practices for Coverage Changes in 2027

- Describe the pending enrollment criteria and barriers to enrollment in Medicaid as well as the Marketplace set in place by the One Big Beautiful Bill Act (OBBBA) and the Marketplace Integrity and Affordability Final Rule.
- Discuss how the new enrollment criteria and barriers for Medicaid as well as the Marketplace may impact insurance coverage, treatment access, and financial burden for patients with chronic medical conditions.

- Identify preparation strategies for oncology care teams for the potential impact of these policy changes on their patient populations.

From Implementation to Impact: Lessons from the NCODA BTCE Mentorship Program
1.0 AMA PRA Category 1 Credit™, AAPA credit and ANCC contact hour
This educational activity is supported by an independent medical education grant from Pfizer.

- Describe the roles, workflows, and resources needed to support bispecific T-cell engager (BTCE) therapy implementation in oncology practice.
- Explain approaches for addressing staff training, toxicity management, REMS processes, care coordination, and transitions of care during BTCE therapy implementation.
- Discuss strategies to combat barriers to BTCE therapy implementation in oncology practice.

Poster Presentations
1.0 AMA PRA Category 1 Credit™, AAPA credit and ANCC contact hour

AI Unfiltered: A Live PQI Podcast on the Future of Oncology
0.75 AMA PRA Category 1 Credit™, AAPA credit and ANCC contact hour

- Define foundational AI concepts including machine learning, generative AI, and large language models.
- Describe key benefits, limitations, and safety considerations associated with the use of AI in healthcare and oncology.
- Identify current and emerging applications of AI in routine oncology care, including diagnosis and patient education and communication.

The Power of the Particle: Nuclear Pharmacy 101
0.75 AMA PRA Category 1 Credit™, AAPA credit and ANCC contact hour

- Describe the basic principles of particulate and non-particulate radiation in how it pertains to cellular toxicity and death.
- Identify when a medication may interfere with the appropriate use of a diagnostic or therapeutic radiopharmaceutical in the detection and treatment of disease.
- Recognize the basic concept of theranostics and its emerging relevance in the oncology space.

Disclosures

Partners for Advancing Clinical Education (Partners) requires every individual in a position to control educational content to disclose all financial relationships with ineligible companies that have occurred within the past 24 months. Ineligible companies are organizations whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients.

All relevant financial relationships for anyone with the ability to control the content of this educational activity are listed below and have been mitigated according to Partners policies. Others involved in the planning of this activity have no relevant financial relationships.

Faculty/Planning Committee Member	Relevant Financial Relationship(s)
Scott Freeswick (planning committee)	Advisory Board: Merck, J&J/Janssen, Genmab, Pharmacosmos, Amneal, AVYXA
Astrid Slaughter, PharmD, PhD, BCOP, BCSCP	Speaker: BeOne, Regeneron; Advisory Board: Celcuity
Jad Chahoud, MD, MPH-MHA	Advisory Board/Consulting: Merck, Pfizer, Exelixis, Aveo, Eisai, and Mycaregorythm
Andrew Cowan, MD	Consultant/Principal Investigator: J&J, Regeneron, Sanofi; Independent Contractor/Consultant/Principal

	Investigator: BMS; Independent Contractor: HopeAI, Consultant: Kite/Arcellx
Elizabeth Rauschenberg, MSN, APRN, FNP-C	Speaker: McKesson
Attaya Suvannasankha, MD	Advisory Board/Principal Investigator: Janssen Oncology, Regeneron, Pfizer; Advisory Board/Principal Investigator/Independent Contractor: BMS; Principal Investigator: C4 Therapeutics; Independent Contractor: Karyopharm
Megan May, PharmD, BCOP, FHOPA, FAPO	Advisory Board/Consultant/Speaker: Amgen, DSI, GSK, Pharmacosmos, Abbie, Genmab
Kelly Brunk, PharmD, MBA, BCOP, NCODA	Speaker: Pfizer
Brooke Adams, PharmD, BCOP	Consultant/Speaker: Amgen, Pfizer, Incyte, GSK, Genmab/Abbie, J&J, Regeneron, Omeros
David Patel, PharmD, BCOP	Advisory Board: Sanofi, Syndax
Vince Sung, PharmD, MBA, BCOP, BCSCP	Advisory Board: Incyte, Urogen, Amgen; Speaker: Janssen
Chadi Nabhan, MD, MBA, FACP	Stockholder: Ryght AI
Nicolo Mastascusa, PharmD, BCNP	Consultant: Novartis
Noor Naffakh	Other: Pfizer; Speaker: Binaytara
Lauren Yarbro	Consultant: Integra Connect; Speaker: MJH Life Sciences
Brooke Looney	Advisory Board: AZ, J&J; Principal Investigator: Takeda
Chelsea Renfro	Principal Investigator: UCB
Manale Maksour	Advisory Board: Pharmacosmos, Gilead
Brooke Peters	Consultant/Speaker: Amgen, Janssen, Regeneron, Pfizer; Advisory Board: Genentech, Regeneron

All other **faculty, planning committee members** and **planners** have no relevant financial relationships.

Joint Accreditation Statement

In support of improving patient care, this activity has been planned and implemented by Partners for Advancing Clinical Education (Partners) and NCODA. Partners is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Physician Continuing Education

Partners designates this live activity for a maximum of 7.25 *AMA PRA Category 1 Credit*(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

PA Continuing Medical Education

Partners has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 7.25 AAPA Category 1 CME credits. PAs should only claim credit commensurate with the extent of their participation.

Nursing Continuing Professional Development

The maximum number of hours awarded for this Nursing Continuing Professional Development activity is 7.25 contact hours.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications. The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient's conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer's product information, and comparison with recommendations of other authorities.

Instructions for Credit

CE Credit for the 2026 NCODA Fall Summit can be claimed through the LecturePanda platform. To register, please visit: https://www.lecturepanda.com/r/2026NCODAFallSummit

2026 NCODA INTERNATIONAL FALL SUMMIT | Essential CE Information

1 REGISTER FOR ON DEMAND CEs

Click link below or scan QR code

https://www.lecturepanda.com/r/2026NCODAFSPosterSessions

After registering, you will receive a confirmation email from lecturepanda with a unique link. **Please do not share this link, it is unique to your profile.**

2 COMPLETE THE POST-ASSESSMENT & EVALUATION

✓

Enter the CE code found on each poster to complete the post-assessment quizzes and evaluation for each CE activity.

3 OBTAINING ON DEMAND CE CREDIT

Complete all LecturePanda credit requirements within 3 years, by:

OCT
27, 2029

Pharmacists; Pharmacy Technicians:

- ACPE credit transmitted electronically

Physicians; Nurses; Nurse Practitioners; Physician Assistants:

- Refer to the PACE handout*

*All CE posters except “Expanded Institutional Experience with Prophylactic Tocilizumab for Outpatient Bispecific Antibody Administration in Community Oncology” and “Real-World Experience with Abatacept for Immune Checkpoint Inhibitor-Associated Myocarditis: Patient Characteristics and Hospital Outcomes” are available for AMA/AAPA/ANCC On-Demand CE

2026 NCODA INTERNATIONAL FALL SUMMIT

2026 NCODA Fall Summit CE Poster Presentations (On Demand)

Claim 0.25 CE Hours of On Demand Continuing Education Credit for each Poster

- **Pharmacists; Pharmacy Technicians:** ACPE credit transmitted electronically
- **Physicians; Nurses; Nurse Practitioners; Physician Assistants:** Refer to the PACE handout*
  *All CE posters except "Expanded Institutional Experience with Prophylactic Tocilizumab for Outpatient Bispecific Antibody Administration in Community Oncology" and "Real-World Experience with Abatacept for Immune Checkpoint Inhibitor-Associated Myocarditis: Patient Characteristics and Hospital Outcomes" are available for AMA/AAPA/ANCC On-Demand CE

CE CODE | 2026 NCODA INTERNATIONAL FALL SUMMIT

CE Codes available for On-Demand are on the posters and can be viewed under the "Materials" tab on Lecture Panda.

How to Claim Your On Demand CE Credit

1. **Attend and participate in the live CE poster session.**
2. **Return to LecturePanda and enter the CE claim code found on each poster.**
3. **Complete the required CE Post-Assessment and Evaluation.**

Complete all On Demand CE requirements in LecturePanda by **October 27, 2029**

Partners for Advancing Clinical Education

2026 NCODA Fall Summit – Poster Enduring Archives CE Information

Launch Date: 10/27/26
Expiration Date: 10/27/29

Estimated time to complete each poster: 15 minutes
Provided by Partners for Advancing Clinical Education and NCODA

Target Audience

This conference is intended for oncology healthcare providers that include; pharmacists, pharmacy technicians, physicians and nurses who care for patients within oncology

Poster Educational Objectives

Upon completion of the poster, participants should be able to:

From Triage to Teaching: Preparing Preceptors for What's Next
0.25 AMA PRA Category 1 Credit™, AAPA credit and ANCC contact hour

- Describe evidence-based communication, coaching, and feedback strategies that support effective preceptor development and improve onboarding outcomes across healthcare practice settings.

Developing a Comprehensive Community-Based Bispecific Antibody Operations Program for Safe Step-Up Dosing and Ongoing Management
0.25 AMA PRA Category 1 Credit™, AAPA credit and ANCC contact hour

- Describe the key operational, clinical, educational, and multidisciplinary components of a community-based bispecific antibody program that support safe step-up dosing, toxicity monitoring, caregiver engagement, adverse event management, and implementation across oncology practice settings.

Beyond Staffing Gaps: A Scalable Nursing Float Pool Model for Integrated Oncology Care
0.25 AMA PRA Category 1 Credit™, AAPA credit and ANCC contact hour

- Describe how a standardized interdisciplinary Float Pool model can be implemented and adapted to support staffing stability, continuity of care, patient access, and safe, consistent oncology practice across sites.

Social Drivers of Health and Progression-Free Survival in Metastatic Breast Cancer Patients on Cyclin-Dependent (CDK) 4/6 Inhibitors
0.25 AMA PRA Category 1 Credit™, AAPA credit and ANCC contact hour

- Identify social drivers of health, such as race, insurance status, distance to care, and employment status, that impact progression-free survival (PFS), duration of therapy, and time to discontinuation in patients with HR positive, HER2-negative, metastatic breast cancer on CDK 4/6 inhibitors.

GLP-1 Agonists and Breast Cancer Outcomes: Emerging Advancements in Metabolic Oncology
0.25 AMA PRA Category 1 Credit™, AAPA credit and ANCC contact hour

- Explain how GLP-1 receptor agonist mediated metabolic pathways, including inflammation reduction and adipose related estrogen modulation, may influence breast cancer incidence, recurrence-free survival, and overall survival.

Implementation and Safety of an Outpatient Bispecific T-Cell Engager Program within a Community Oncology Network

0.25 AMA PRA Category 1 Credit™, AAPA credit and ANCC contact hour

- Determine if bispecific T-cell engagers may be administered safely in the outpatient setting by independent community oncology practices.

Oncology Optimized Limited Distribution: Real-World Pharmacist Feedback on Awareness, Workflow Integration, and Practice Change

0.25 AMA PRA Category 1 Credit™, AAPA credit and ANCC contact hour

- Identify key findings and proposed next steps regarding the Oncology Optimized Limited Distribution (OOLD) model in oncology pharmacy practice.

Healthcare Professional Perceptions of the Accuracy and Usability of Patient Education Sheets

0.25 AMA PRA Category 1 Credit™, AAPA credit and ANCC contact hour

- Describe healthcare professionals' perceptions of the clinical accuracy and usability of Patient Education Sheets (PES).

Extramedullary Relapse of IgA Lambda Multiple Myeloma Presenting as Cutaneous Tumor Localized to an Incision Scar: A Case Report

0.25 AMA PRA Category 1 Credit™, AAPA credit and ANCC contact hour

- Describe the clinical presentation, proposed disease mechanisms, and approaches to evaluation and management of extramedullary relapse of multiple myeloma in the case presented in this poster.

Circulating Tumor DNA (ctDNA) as a Biomarker to Guide Treatment Escalation and De-Escalation in Non-Small Cell Lung Cancer (NSCLC): A Review of the Current Evidence

0.25 AMA PRA Category 1 Credit™, AAPA credit and ANCC contact hour

- Summarize current evidence and limitations regarding the use of ctDNA to inform treatment escalation, de-escalation, and surveillance strategies in non-small cell lung cancer (NSCLC).

Improving Temperature Excursion Decision-Making for Specialty Oncology Medications Through Manufacturer Outreach

0.25 AMA PRA Category 1 Credit™, AAPA credit and ANCC contact hour

- Identify key considerations for managing shipment-related temperature excursions involving specialty oncology medications, including storage requirements, manufacturer outreach, and use of a standardized decision-making framework.

Optimizing Clinical Trial Workflow: Elevating the Role of the Pharmacy Technician within Investigational Drug Services

0.25 AMA PRA Category 1 Credit™, AAPA credit and ANCC contact hour

- Describe the roles and operational impact of pharmacy technicians within oncology Investigational Drug Services, including their contributions to regulatory compliance, audit readiness, workflow efficiency, and pharmacist resource allocation.

Waste Not: How Drug Data Access Transforms Oncology Compounding Efficiency

0.25 AMA PRA Category 1 Credit™, AAPA credit and ANCC contact hour

- Explain how implementing centralized, accessible drug information resources can improve compounding accuracy, enhance operational efficiency, and minimize drug waste during the preparation of high-cost oncology therapies.

Upcoming Medicare Part D Changes for 2027: What Oncology Practices Need to Know
0.25 AMA PRA Category 1 Credit™, AAPA credit and ANCC contact hour

- Describe key 2027 Medicare Part D changes and their potential implications for oncology medication access, affordability, and pharmacy operations.

Implementing a Health-System-Wide Vial Optimization Initiative to Reduce Medication Waste and Improve Financial Stewardship
0.25 AMA PRA Category 1 Credit™, AAPA credit and ANCC contact hour

- Identify methods to reduce medication waste across a health system through standardized vial optimization practices, cross-site collaboration, and data-driven monitoring while establishing a sustainable framework for ongoing performance measurement and benchmarking.

Disclosures

Partners for Advancing Clinical Education (Partners) requires every individual in a position to control educational content to disclose all financial relationships with ineligible companies that have occurred within the past 24 months. Ineligible companies are organizations whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients.

All relevant financial relationships for anyone with the ability to control the content of this educational activity are listed below and have been mitigated according to Partners policies. Others involved in the planning of this activity have no relevant financial relationships.

Faculty/Planning Committee Member	Relevant Financial Relationship(s)
Scott Freeswick (planning committee)	Advisory Board: Merck, J&J/Janssen, Genmab, Pharmacosmos, Amneal, AVYXA
Noor Naffakh	Other: Pfizer; Speaker: Binaytara
Elizabeth Rauschenberg	Speaker: McKesson
Lauren Yarbro	Consultant: Integra Connect; Speaker: MJH Life Sciences
Brooke Looney	Advisory Board: AZ, J&J; Principal Investigator: Takeda
Chelsea Renfro	Principal Investigator: UCB
Manale Maksour	Advisory Board: Pharmacosmos, Gilead
Brooke Peters	Consultant/Speaker: Amgen, Janssen, Regeneron, Pfizer; Advisory Board: Genentech, Regeneron
Kelly Brunk	Speaker: Pfizer

All other **faculty, authors, planning committee members** and **planners** have no relevant financial relationships.

Joint Accreditation Statement

JOINTLY ACCREDITED PROVIDER™
INTERPROFESSIONAL CONTINUING EDUCATION

In support of improving patient care, this activity has been planned and implemented by Partners for Advancing Clinical Education (Partners) and NCODA. Partners is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Physician Continuing Education

Partners designates this enduring material for a maximum of 3.75 *AMA PRA Category 1 Credit*(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

PA Continuing Medical Education

Partners has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 3.75 AAPA Category 1 CME credits. Approval is valid until **10/27/29.** PAs should only claim credit commensurate with the extent of their participation.

Nursing Continuing Professional Development

The maximum number of hours awarded for this Nursing Continuing Professional Development activity is 3.75 contact hours.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications. The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient's conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer's product information, and comparison with recommendations of other authorities.

Instructions for Credit

CE Credit for the Poster Archives from the 2026 Spring Forum can be claimed through the LecturePanda platform. To register, please visit: **https://www.lecturepanda.com/r/2026NCODAFSPosterSessions**